Issues pertaining to access to, coverage of and reimbursement for dialysis services and kidney care, including integrated and coordinated care, including but not limited to H.R. 8254/S. 4574, the Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act (116th Congress).
Issues pertaining to administrative proposals for new value-based purchasing models for dialysis services; policies contained in 85 FR 33796, Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program.
Policies contained in P.L. 117-7, to prevent across-the-board direct spending cuts, and for other purposes.
Issues pertaining to access to, coverage of, and reimbursement for kidney care, including charitable premium assistance, kidney disease education, and anti-kickback issues. Issues pertaining to the COVID-19 response, including but not limited to the vaccination of kidney patients and providers.
Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.
Duration: October 1, 2019
to
April 8, 2021
General Issues: Medicare/Medicaid , Health Issues
Spending: about $300,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jennifer Bell Health Policy Advisor, Sen. Finance Committee
Legislative Assistant, Rep. John Thune (R-SD)
Melissa Bartlett Privacy Program Specialist, U.S. Department of Health and Human Services, Office of the Secretary, Office for Civil Rights
Counsel, U.S. House of Representatives, Committee on Energy and Commerce
Anna Weinstein n/a
Ariel Gonzalez n/a
Deema Tarazi n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2021
Chamber Hill Strategies terminated an engagement in which they represented American Renal Associates on July 19, 2021.
Original Filing: 301280713.xml
Lobbying Issues
Issues pertaining to access to, coverage of and reimbursement for dialysis services and kidney care, including integrated and coordinated care, including but not limited to H.R. 8254/S. 4574, the Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act (116th Congress).
Issues pertaining to administrative proposals for new value-based purchasing models for dialysis services; policies contained in 85 FR 33796, Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program.
Policies contained in P.L. 117-7, to prevent across-the-board direct spending cuts, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to access to, coverage of, and reimbursement for kidney care, including charitable premium assistance, kidney disease education, and anti-kickback issues. Issues pertaining to the COVID-19 response, including but not limited to the vaccination of kidney patients and providers.
Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Chamber Hill Strategies lobbied for American Renal Associates , earning $50,000. The report was filed on April 19, 2021.
Original Filing: 301256329.xml
Lobbying Issues
Issues pertaining to access to, coverage of and reimbursement for dialysis services and kidney care, including integrated and coordinated care, including but not limited to H.R. 8254/S. 4574, the Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act (116th Congress).
Issues pertaining to administrative proposals for new value-based purchasing models for dialysis services; policies contained in 85 FR 33796, Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program.
Policies contained in and amendments to H.R.1868, to prevent across-the-board direct spending cuts, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to access to, coverage of, and reimbursement for kidney care, including charitable premium assistance, kidney disease education, and anti-kickback issues.
Issues pertaining to the COVID-19 response, including but not limited to the vaccination of kidney patients and providers.
Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Chamber Hill Strategies lobbied for American Renal Associates , earning $50,000. The report was filed on Jan. 19, 2021.
Original Filing: 301235022.xml
Lobbying Issues
Issues pertaining to access to, coverage of and reimbursement for dialysis services and kidney care, including integrated and coordinated care, including but not limited to H.R. 8254/S. 4574, the Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act. Issues pertaining to administrative proposals for new value-based purchasing models for dialysis services; policies contained in 85 FR 33796, Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. Health care policies in P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act of CARES Act; and P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, the Heroes Act; H.R. 8406, the Heroes Act; Senate Amendment 2652 related to COVID-19 relief; P.L. 116-159, the Continuing Appropriations Act, 2021 and Other Extensions Act; and P.L.116-260, Consolidated Appropriations Act, 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to access to, coverage of, and reimbursement for kidney care, including charitable premium assistance, kidney disease education, and anti-kickback issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Chamber Hill Strategies lobbied for American Renal Associates , earning $50,000. The report was filed on Oct. 19, 2020.
Original Filing: 301215304.xml
Lobbying Issues
Issues pertaining to: access to, coverage of and reimbursement for dialysis services and kidney care, including integrated and coordinated care, including but not limited to H.R. 8254/S. 4574, the Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act.
Issues pertaining to administrative proposals for new value-based purchasing models for dialysis services; COVID-19 relief for and response by providers; and policies contained in 85 FR 33796, Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. Health care policies in P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act of CARES Act; and P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, the Heroes Act; H.R. 8406, the Heroes Act; Senate Amendment 2652 related to COVID-19 relief; and H.R. 8337, the Continuing Appropriations Act, 2021 and Other Extensions Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to access to, coverage of, and reimbursement for kidney care; including charitable premium assistance, kidney disease education, and anti-kick back issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Chamber Hill Strategies lobbied for American Renal Associates , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301195650.xml
Lobbying Issues
Issues pertaining to: access to, coverage or, and reimbursement for dialysis services and kidney care, including integrated and coordinated care; administrative proposals for new value-based purchasing models for dialysis services; COVID-19 relief for and response by providers; and policies contained in 85 FR 33796, Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. Health care policies in P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act of CARES Act; and P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to access to, coverage of, and reimbursement for kidney care; including charitable premium assistance, kidney disease education, and anti-kick back issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Chamber Hill Strategies lobbied for American Renal Associates , earning $50,000. The report was filed on April 16, 2020.
Original Filing: 301168731.xml
Lobbying Issues
Issues pertaining to access to, coverage of, and reimbursement for dialysis services and kidney care; administrative proposals for new value-based purchasing models for dialysis services, and COVID-19 relief for and response by providers; Health care polices in P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act or CARES Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to access to, coverage of, and reimbursement for kidney care; including charitable premium assistance, kidney disease education, and anti-kick back issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Chamber Hill Strategies lobbied for American Renal Associates , earning $50,000. The report was filed on Jan. 15, 2020.
Original Filing: 301106129.xml
Lobbying Issues
Issues pertaining to access to, coverage of, and reimbursement for dialysis services and kidney care; administrative proposals for new value-based purchasing models for dialysis services.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to access to, coverage of, an reimbursement for kidney care.
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...